Cellectar Biosciences (CLRB) AI Stock Analysis

• Market Cap: $16.86M
• Dividend Yield: N/A
• Average Volume (3M): 23.53M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: N/A
• EPS Growth: 56.38%
• Country: US
• Employees: 11
• Sector: Healthcare
• Sector Strength: 55
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 46,079,876
• 10 Day Avg. Volume: 69,081,313
• 30 Day Avg. Volume: 23,532,251
• PEG Ratio: 0.07
• Price to Book (P/B): 0.78
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.47
• Enterprise Value/Market Cap: -0.43
• Enterprise Value/Revenue: -7.26
• Enterprise Value/Gross Profit: 46.58
• Enterprise Value/Ebitda: 0.04
• 1Y Price Target: $3.00
• Price Target Upside: 581.82% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 34 Underperform
• Price Target: ―

Cellectar Biosciences faces significant financial challenges with no revenue generation and heavy reliance on external financing. Technical indicators suggest a bearish trend, and the company's valuation is weakened by negative earnings. Although the earnings call highlighted some clinical and regulatory progress, these are overshadowed by financial and operational setbacks, leading to a below-average overall stock score.

Positive Factors

Financial Position

The company has $34M in cash (above the market cap of ~$10M) and with reduced opex, should have runway into late 2025 and paths forward with earlier-stage assets on what is viewed as a de-risked PDC platform.

Market Opportunities

The radiopharma space is described as active with new opportunities ahead, suggesting potential growth for Cellectar Biosciences.

Regulatory Approval

Cellectar recently held a meeting with the FDA, which confirmed a clear path to accelerated approval for Iopofosine-131 in Waldenstrom’s macroglobulinemia.

Negative Factors

Earnings Performance

Cellectar filed its 10-Q and reported 1Q25 results with a net loss of ($6.6M) and ended the period with $13.9M in cash on the balance sheet, which should fund the company into 4Q25.

Regulatory Challenges

Cellectar announced that after discussions with FDA, the agency is requiring a confirmatory study to support accelerated approval for Iopofosine-131 in Waldenstrom’s macroglobulinemia (WM).

Strategic Uncertainty

As the company now seeks strategic alternatives for its assets, there is significant uncertainty regarding the future development of these programs.

Cellectar Biosciences Business Overview & Revenue Model

Company Description

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

How the Company Makes Money

Cellectar Biosciences makes money primarily through the development and commercialization of its targeted cancer therapies. The company's revenue model is largely dependent on the successful advancement of its drug candidates through clinical trials and eventual approval by regulatory bodies. Additionally, Cellectar may generate revenue through partnerships, licensing agreements, and collaborations with larger pharmaceutical companies, enabling shared development costs and promotional activities. These partnerships can provide upfront payments, milestone payments, and royalties on sales upon successful commercialization of their therapies.

Cellectar Biosciences Financial Statement Overview

Summary

Cellectar Biosciences is in a challenging financial position with zero revenue generation and continuous operational losses. The company heavily relies on external financing for cash flow needs, and its balance sheet shows vulnerabilities with negative or fluctuating equity. The consistent lack of revenue and profitability raises significant concerns about its financial sustainability.

Income Statement

Cellectar Biosciences has consistently reported zero revenue over the years, indicating a lack of commercialized products. The company operates at a loss, with significant negative net income each year. The EBIT and EBITDA margins are negative, reflecting operational challenges and lack of profitability.

Balance Sheet

The company exhibits a high dependency on equity financing, as seen in fluctuating stockholder's equity and negative equity in 2023. The debt-to-equity ratio is low, indicating limited use of debt, but the overall financial position is weak due to ongoing losses and negative equity in recent years.

Cash Flow

Cellectar Biosciences shows recurring negative free cash flow, indicating insufficient cash generation from operations. The company relies on financing activities to sustain operations, as evidenced by large financing cash inflows. Operating cash flow has been consistently negative, reflecting operational inefficiencies.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-192.38K	-238.87K	-227.64K	-207.93K
	EBIT
-51.78M	-38.96M	-28.81M	-24.13M	-15.29M
	EBITDA
-44.22M	-38.77M	-28.67M	-23.98M	-15.15M
	Net Income Common Stockholders
-44.58M	-37.98M	-28.60M	-23.97M	-14.76M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
23.29M	9.56M	19.87M	35.70M	57.17M
	Total Assets
25.47M	12.08M	21.59M	37.20M	58.66M
	Total Debt
494.00K	552.98K	603.83K	301.74K	421.64K
	Net Debt
-22.79M	-9.01M	-19.26M	-35.40M	-56.74M
	Total Liabilities
11.18M	25.85M	6.08M	4.16M	3.86M
	Stockholders Equity
14.29M	-15.16M	15.51M	33.05M	54.79M
Cash Flow		Free Cash Flow
-47.69M	-33.24M	-25.45M	-22.71M	-14.00M
	Operating Cash Flow
-47.58M	-32.38M	-25.22M	-22.57M	-13.93M
	Investing Cash Flow
-104.19K	-864.04K	-225.97K	-141.36K	-62.35K
	Financing Cash Flow
61.41M	22.94M	9.61M	1.25M	60.55M

Cellectar Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.44
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLRB, the sentiment is Positive. The current price of 0.44 is above the 20-day moving average (MA) of 0.31, above the 50-day MA of 0.29, and below the 200-day MA of 0.92, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 69.33 is Neutral, neither overbought nor oversold. The STOCH value of 36.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLRB.

Cellectar Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
SLGL	51 Neutral	$19.25M	―	-49.39%	―	473.46%	62.25%
AKTX	44 Neutral	$36.10M	―	-197.11%	―	―	―
CANF	42 Neutral	$14.53M	―	-122.28%	―	―	―
CLRB	34 Underperform	$16.86M	―	-208.72%	―	―	56.38%
GOVX	34 Underperform	$18.54M	―	-616.17%	―	―	71.39%
ELEV	33 Underperform	$22.66M	―	-78.32%	―	―	47.73%

Cellectar Biosciences Corporate Events

Cellectar Biosciences Enhances CEO and COO Severance Benefits

On March 12, 2025, Cellectar Biosciences’ board approved amendments to the employment agreements of its CEO and COO, enhancing their severance benefits in the event of a change in control. Additionally, on March 11, 2025, the board adopted new by-laws to align with Delaware law, revising stockholder nomination procedures and reducing the quorum requirement for meetings.